Pulmonary Arterial Hypertension Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies By DelveInsight

Posted on
by

Pulmonary Arterial Hypertension Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies By DelveInsight

Pulmonary Arterial Hypertension Market Insight Report
DelveInsight’s “Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on Pulmonary Arterial Hypertension Market Insights, Epidemiology and Market Forecast-2030  

The Pulmonary Arterial Hypertension market report provides current treatment practices, emerging drugs, Pulmonary Arterial Hypertension market share of the individual therapies, current and forecasted Pulmonary Arterial Hypertension Pain market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Pulmonary Arterial Hypertension treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

Key benefits of the report
1. Pulmonary Arterial Hypertension market report covers a descriptive overview and comprehensive insight of the Pulmonary Arterial Hypertension Epidemiology and Pulmonary Arterial Hypertension market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) 
2. Pulmonary Arterial Hypertension market report provides insights on the current and emerging therapies.
3. Pulmonary Arterial Hypertension market report provides a global historical and forecasted market covering drug outreach in 7 MM.   
4. Pulmonary Arterial Hypertension market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Pulmonary Arterial Hypertension market.

“The disease is found to be more common among women as compared to men”

Pulmonary Arterial Hypertension therapeutic market is driven by the use of endothelin receptor antagonists, prostanoids, and phosphodiesterase inhibitors for the Pulmonary Arterial Hypertension treatment. Among these therapeutics endothelin receptor antagonists are most widely used for the treatment of Pulmonary Arterial Hypertension.

 

LetairisVolibris, Opsumit, and Tracleer are mostly recommended endothelin receptor antagonists being used for the Pulmonary Arterial Hypertension treatment. These antagonists act by relaxing blood vessels and inhibiting proliferation and remodelling of blood vessels. LetairisVolibris is a selective Endothelin Type-A (ETA) receptor antagonist is the most robust therapeutic as compared to the other endothelin receptor antagonists (ERAs).   

 

Drugs covered

  1. 1.           Aurora-GT
  2. 2.           Ralinepag
  3. 3.           Bardoxolone Methyl
  4. 4.           Rodatristat Ethyl
  5. 5.           Sotatercept

And many others

The key players in Pulmonary Arterial Hypertension market are:

  1. United Therapeutics
  2. Liquidia Technologies
  3. Reata Pharmaceuticals
  4. Altavant Sciences
  5. Acceleron Pharma

And many others

Table of contents

1. Key Insights

2. Executive Summary of Pulmonary Arterial Hypertension

3. SWOT Analysis for Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension Market Overview at a Glance

5. Pulmonary Arterial Hypertension Disease Background and Overview

6. Pulmonary Arterial Hypertension Epidemiology and Patient Population

7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)

7.1. The United States

7.2. Germany

7.3. France

7.4. Italy

7.5. Spain

7.6. The United Kingdom

7.7. Japan

8. Pulmonary Arterial Hypertension Treatment Algorithm

9. Unmet Needs

10. Case Studies

11. Organizations related with Pulmonary Arterial Hypertension

12. Pulmonary Arterial Hypertension Marketed Drugs

12.1.Approval and Market Presence

13. Pulmonary Arterial Hypertension Marketed Drugs by Companies

13.1.United Therapeutics Corporation

13.2.Johnson & Johnson

13.3.GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.

13.4.Bayer AG

13.5. Pfizer

14. Safety and Efficacy of Marketed Drugs

15. Pulmonary Arterial Hypertension Emerging Therapies

15.1. Emerging Drugs Analysis

15.2.Aurora-GT: United Therapeutics

15.3.Ralinepag: United Therapeutics

15.5.Bardoxolone Methyl: Reata Pharmaceuticals

15.6.Rodatristat Ethyl: Altavant Sciences

15.7. Sotatercept: Acceleron Pharma

15.8. PB1064: PhaseBio Pharmaceuticals

15.9. CXA-10: Complexa

16. Other Promising Candidates

16.1. Inhaled Nitric Oxide: Bellerophon Pulse Technologies

16.2.RT234: Respira Therapeutics

17. Pulmonary Arterial Hypertension 7 Major Market Analysis

18. United States

19. EU5 Countries

19.1.Germany

19.2. France

19.3. Italy

19.4. Spain

19.5.United Kingdom

20. Japan

21. Market Drivers

22. Market Barriers

23. Appendix

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

 

Related Reports:

DelveInsight’s Pulmonary Arterial Hypertension (PAH) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Pulmonary Arterial Hypertension (PAH) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Pulmonary Arterial Hypertension Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Pulmonary Arterial Hypertension market.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Priya Maurya
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/